NeuroIentech

Neurolentech was founded in late 2020 as a spin-out from IST Austria to identify new treatments for neurodevelopmental diseases. We use the latest scientific laboratory techniques to develop patient-derived neuronal cell models that give us insights into the molecular mechanisms of disease. We use these insights to develop new potential treatments in close partnership with biopharma companies.